(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/179561 A1

(51) International Patent Classification:
C07K 16/30 (2006.01) *A61K 39/395* (2006.01)
C07K 16/28 (2006.01) *A61K 31/4745* (2006.01)
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CN2024/079518

(22) International Filing Date:
01 March 2024 (01.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2023/079311
02 March 2023 (02.03.2023) CN

(71) Applicant: **MULTITUDE THERAPEUTICS INC.** [CN/CN]; 101, 201, 301, 401, Unit 10, No.159 Tianzhou Road, Xuhui District, Shanghai 200233 (CN).

(72) Inventors: **MENG, Xun**; C/o Multitude Therapeutics Inc., 101, 201, 301, 401, Unit 10, No.159 Tianzhou Road, Xuhui District, Shanghai 200233 (CN). **LIU, Shu-Hui**; C/o Multitude Therapeutics Inc., 101, 201, 301, 401, Unit 10, No.159 Tianzhou Road, Xuhui District, Shanghai 200233 (CN). **WANG, Yixuan**; C/o Multitude Therapeutics Inc., 101, 201, 301, 401, Unit 10, No.159 Tianzhou Road, Xuhui District, Shanghai 200233 (CN).

(74) Agent: **WINGUAN PATENT AND TRADEMARK ATTORNEYS**; HE, Jinbiao, Tower A 2317, China Shine Plaza, 9 Linhe Xi Road, Tianhe District, Guangzhou, Guangdong 510610 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2024/179561 A1

(54) Title: ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

(57) Abstract: Antibody-drug conjugates and pharmaceutical compositions thereof and methods of treating cancer therewith. The antibody-drug conjugates are conjugates of belotecan derivatives and anti-CD44v9 antibodies or antigen binding fragments thereof. The antibody-drug conjugates exhibit superior anti-tumor activity in various solid tumors.